Clinical Trials Directory

We are doing this study to understand how hand transplantation can help you with your daily activities compared to before the transplant.

We are doing this study to better understand how HIV affects the body.

The purpose of this study is to find out if combining a bispecific antibody with a drug called selinexor (XPOVIO) is a safe and effective option for multiple myeloma patients whose disease has returned after treatment or did not adequately respond to treatment.

This study lasts about 28 weeks. The first 12 weeks are used to check if a person can join. Then there are 24 weeks of treatment and 4 weeks of follow up. People are put into groups by chance. Some will get the study medicine called resmetirom and some will get a pill that has no medicine in it. No one will know which pill they receive. During the study, people will have regular visits for blood tests, liver scans, check ups, and safety checks to watch for any side effects.

We are doing this study to find out if an experimental drug called pacritinib (the study drug) is a safe and effective treatment for people with T-cell lymphoproliferative cancers. We want to know how well it works for patients diagnosed with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL).

We are doing this study to collect blood samples that may be used for the following:

• To make sure equipment and assays are working properly
• Staff training
• Researching assay development (an assay is a laboratory test)

We are doing this study to find out if an experimental drug called HLX43 (the study drug) is a safe and beneficial option for people with non-small cell lung cancer (NSCLC) that did not respond favorably to standard treatments.

We are doing this study to find out if an experimental drug called etavopivat (the study drug) is a safe and effective option for children and adolescents who have SCD.